Evidence map›Paper›PMID 31277598›Full record

ArticleBMC cancer2019

Novel significant stage-specific differentially expressed genes in hepatocellular carcinoma.

Arjun Sarathi, Ashok Palaniappan

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 77 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Frontiers in immunology · 2025
    Article
  10. Article
  11. Unveiling the Bioactive Efficacy ofPharmaceuticals (Basel, Switzerland) · 2024
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Gamma-Aminobutyric Acid Type A Receptor Subunit Delta (Iranian journal of public health · 2023
    Article
  17. Article
  18. Article
  19. Age-dependent expression of ion channel genes in rat.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2023
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Arjun SarathiDepartment of Bioengineering, School of Chemical and BioTechnology, SASTRA deemed University, Thanjavur, Tamil Nadu, 613401, India.
Ashok PalaniappanDepartment of Bioinformatics, School of Chemical and BioTechnology, SASTRA deemed University, Thanjavur, Tamil Nadu, 613401, India. apalania@scbt.sastra.edu.ORCID http://orcid.org/0000-0003-2841-9527
SASTRA University · IN

Funding

Science and Engineering Research Board EMR/2017/000470
6 · The paper itself

Abstract

backgroundLiver cancer is among top deadly cancers worldwide with a very poor prognosis, and the liver is a vulnerable site for metastases of other cancers. Early diagnosis is crucial for treatment of the predominant liver cancers, namely hepatocellular carcinoma (HCC). Here we developed a novel computational framework for the stage-specific analysis of HCC.

methodsUsing publicly available clinical and RNA-Seq data of cancer samples and controls and the AJCC staging system, we performed a linear modelling analysis of gene expression across all stages and found significant genome-wide changes in the log fold-change of gene expression in cancer samples relative to control. To identify genes that were stage-specific controlling for confounding differential expression in other stages, we developed a set of six pairwise contrasts between the stages and enforced a p-value threshold (< 0.05) for each such contrast. Genes were specific for a stage if they passed all the significance filters for that stage. The monotonicity of gene expression with cancer progression was analyzed with a linear model using the cancer stage as a numeric variable.

resultsOur analysis yielded two stage-I specific genes (CA9, WNT7B), two stage-II specific genes (APOBEC3B, FAM186A), ten stage-III specific genes including DLG5, PARI, NCAPG2, GNMT and XRCC2, and 35 stage-IV specific genes including GABRD, PGAM2, PECAM1 and CXCR2P1. Overexpression of DLG5 was found to be tumor-promoting contrary to the cancer literature on this gene. Further, GABRD was found to be signifincantly monotonically upregulated across stages. Our work has revealed 1977 genes with significant monotonic patterns of expression across cancer stages. NDUFA4L2, CRHBP and PIGU were top genes with monotonic changes of expression across cancer stages that could represent promising targets for therapy. Comparison with gene signatures from the BCLC staging system identified two genes, HSP90AB1 and ARHGAP42. Gene set enrichment analysis indicated overrepresented pathways specific to each stage, notably viral infection pathways in HCC initiation.

conclusionsOur study identified novel significant stage-specific differentially expressed genes which could enhance our understanding of the molecular determinants of hepatocellular carcinoma progression. Our findings could serve as biomarkers that potentially underpin diagnosis as well as pinpoint therapeutic targets.

Indexed as

TranscriptomeAdultAgedBiomarkers, TumorCarcinoma, HepatocellularEarly Detection of CancerFemaleGene ExpressionGene Expression ProfilingGTPase-Activating ProteinsHSP90 Heat-Shock ProteinsHumansLinear ModelsLiver NeoplasmsMaleMiddle AgedARHGAP42 protein, humanBiomarkers, TumorGTPase-Activating ProteinsHSP90AB1 protein, humanHSP90 Heat-Shock ProteinsCancer progressionDifferentially expressed genesHCC stagesLIHC transcriptomicsLinear modellingMetastasisMonotonic expressionPairwise contrastsSignificance analysisStage-specific biomarkersTumorigenesis

Identifiers

PMID31277598
PMCPMC6612102
OpenAlexW2953462471

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.